Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Jacobi

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2025
Analysis of a Modified Version of the Inventory of Non-Ataxia Signs Over 12 Years in Patients with Friedreich's Ataxia in the EFACTS StudyStella Andrea Lischewski, Imis Dogan, Paola Giunti, et al.
Neurobiology of Disease|February 7, 2026
Cognitive impairment in SCA3: A multi-center cohort study with demographic, imaging, and biomarker correlatesRoderick P P W M Maas, Hector Garcia-Moreno, Jennifer Faber, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 16, 2021
Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral BloodJeannette Hübener-Schmid, Kirsten Kuhlbrodt, Julien Peladan, et al.
Journal of Neurology|April 17, 2025
Optimizing selectivity of the Cerebellar Cognitive Affective Syndrome Scale by use of correction formulas, and validation of its German versionAndreas Thieme, Kerstin Rubarth, Raquel van der Veen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 29, 2021
Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease SeverityHolger Hengel, Peter Martus, Jennifer Faber, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 9, 2022
Differential Temporal Dynamics of Axial and Appendicular Ataxia in SCA3Roderick P P W M Maas, Steven Teerenstra, Manuela Lima, et al.
CNS Drugs|October 17, 2025
The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI CohortPatrick Silva, Marina A Costa, Laetitia Gaspar, et al.
The Lancet. Neurology|May 28, 2013
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline dataHeike Jacobi, Kathrin Reetz, Sophie Tezenas du Montcel, et al.
The Lancet. Neurology|August 22, 2020
Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort studyHeike Jacobi, Sophie Tezenas du Montcel, Sandro Romanzetti, et al.
Journal of Neurology|November 3, 2022
The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2025
Analysis of a Modified Version of the Inventory of Non-Ataxia Signs Over 12 Years in Patients with Friedreich's Ataxia in the EFACTS StudyStella Andrea Lischewski, Imis Dogan, Paola Giunti, et al.
Neurobiology of Disease|February 7, 2026
Cognitive impairment in SCA3: A multi-center cohort study with demographic, imaging, and biomarker correlatesRoderick P P W M Maas, Hector Garcia-Moreno, Jennifer Faber, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 16, 2021
Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral BloodJeannette Hübener-Schmid, Kirsten Kuhlbrodt, Julien Peladan, et al.
Journal of Neurology|April 17, 2025
Optimizing selectivity of the Cerebellar Cognitive Affective Syndrome Scale by use of correction formulas, and validation of its German versionAndreas Thieme, Kerstin Rubarth, Raquel van der Veen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 29, 2021
Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease SeverityHolger Hengel, Peter Martus, Jennifer Faber, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 9, 2022
Differential Temporal Dynamics of Axial and Appendicular Ataxia in SCA3Roderick P P W M Maas, Steven Teerenstra, Manuela Lima, et al.
CNS Drugs|October 17, 2025
The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI CohortPatrick Silva, Marina A Costa, Laetitia Gaspar, et al.
The Lancet. Neurology|May 28, 2013
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline dataHeike Jacobi, Kathrin Reetz, Sophie Tezenas du Montcel, et al.
The Lancet. Neurology|August 22, 2020
Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort studyHeike Jacobi, Sophie Tezenas du Montcel, Sandro Romanzetti, et al.
Journal of Neurology|November 3, 2022
The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Pageof 7